drugset
drugset / Trial / NCT04453618

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

NCT04453618 ↗

Phase 1 Unknown 42 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Multiple Doses Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Including Food Effect) of SYHA1402 in Healthy Subjects.

Timeline

Start
2020-08
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SYHA1402 Unknown 25 mg Oral
Subject SYHA1402 Unknown 50 mg Oral
Subject SYHA1402 Unknown 100 mg Oral
Subject SYHA1402 Unknown 150 mg Oral

Indications

diabetic polyneuropathy